ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion

https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fiscal-2024-second-quarter-financial-results Accuray Reports Fiscal 2024 Second Quarter Financial Results 19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance

.

Accuray Reports Fiscal 2024 First Quarter Financial Results https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fiscal-2024-first-quarter-financial-results Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance

https://www.massdevice.com/accuray-lays-off-nearly-6-of-global-workforce/

Accuray (ARAY) Positioned for Growth: Buy Rating Supported by Chinese Market Expansion, New Product Launches, and Strong Financial Projections https://markets.businessinsider.com/news/stocks/accuray-aray-positioned-for-growth-buy-rating-supported-by-chinese-market-expansion-new-product-launches-and-strong-financial-projections-1032677267

https://www.benzinga.com/pressreleases/23/10/n35072403/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-me

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting https://investors.accuray.com/news-releases/news-release-details/accuray-and-limbus-ai-unveil-online-adaptive-therapy-solution ...Cenos is designed to enable medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table. ...

.

https://finance.yahoo.com/news/accurays-aray-treatment-options-boosted-133000149.html

👀

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market https://www.prnewswire.com/news-releases/accuray-receives-fda-clearance-for-vitalhold-on-the-radixact-system-breast-cancer-treatment-option-will-also-be-available-in-the-eu-market-301895530.html

Accuray GAAP EPS of -$0.03 misses by $0.04, revenue of $118.3M misses by $3.44M https://seekingalpha.com/news/4000416-accuray-gaap-eps-of-0_03-misses-0_04-revenue-of-118_3m-misses-3_44m • Accuray press release (NASDAQ:ARAY): Q4 GAAP EPS of -$0.03 misses by $0.04. • Revenue of $118.3M (+7.5% Y/Y) misses by $3.44M. • The Company is introducing guidance for fiscal year 2024 as follows: • Total revenue is expected in the range of $460 million to $470 million vs $451.05M consensus, representing a year-over-year growth range of 3% to 5%. • Adjusted EBITDA is expected in the range of $27 million to $30 million.

Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2023-financial-results-301896647.html 8% Q4 revenue growth; Record shipments for FY23; Company issues guidance for FY24 

Accuray Incorporated Announces Its Addition to the Russell 2000® Index https://www.prnewswire.com/news-releases/accuray-incorporated-announces-its-addition-to-the-russell-2000-index-301862564.html ...announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, which will be effective today. ...

Cognizant is Partnering with Accuray to Accelerate Corporate Transformation and Drive Operational Efficiency in Their Radiation Therapy Business https://www.prnewswire.com/news-releases/cognizant-is-partnering-with-accuray-to-accelerate-corporate-transformation-and-drive-operational-efficiency-in-their-radiation-therapy-business-301854500.html

https://www.prnewswire.com/news-releases/accuray-cyberknife-and-tomotherapy-platforms-featured-in-more-than-55-abstracts-presented-at-estro-2023-reinforcing-systems-versatility-efficiency-and-effectiveness-301826913.html